May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Palladium-103 Plaque Brachytherapy for Uveal Melanoma: 17 Years Experience
Author Affiliations & Notes
  • P. T. Finger
    The New York Eye Cancer Center, New York, New York
    The New York Eye and Ear Infirmary, New York, New York
  • S. Krishna
    The New York Eye Cancer Center, New York, New York
  • K. Chin
    The New York Eye Cancer Center, New York, New York
  • G. Duvall
    Theragenics Corporation, Buford, Georgia
  • Footnotes
    Commercial Relationships  P.T. Finger, None; S. Krishna, None; K. Chin, None; G. Duvall, E, E.
  • Footnotes
    Support  The EyeCare Foundation, Inc, New York City, New York, and Theragenics Corporation, Buford, Georgia.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 42. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. T. Finger, S. Krishna, K. Chin, G. Duvall; Palladium-103 Plaque Brachytherapy for Uveal Melanoma: 17 Years Experience. Invest. Ophthalmol. Vis. Sci. 2008;49(13):42. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate the long term safety and efficacy of palladium-103 plaque radiation therapy for uveal melanoma.

 
Methods:
 

A retrospective review of the results of 384 consecutively treated patients was performed. Each was treated over 5-7 continuous days, to a mean apex dose of 71 Gy. They were evaluated for tumor and patient specific characteristics as well as local control, visual acuity and eye retention.

 
Results:
 

There were 233 tumors posterior to the equator, 27 equatorial and 122 anterior melanomas. By AJCC-UICC classification there were 69-T1, 293-T2, 17-T3 and 4-T4 melanomas. In 1990, we treated the first patient with palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma. Now, 17-years later, the maximum follow-up is 205 months (mean, 47 months). There have been 13 incidents of tumor regrowth for a 97% local radiation control rate. Only 3% have required secondary enucleation. Best corrected visual acuities are 20/200 or better in 76% (291/384). This may be due (in part) to laser and bevacizumab treatment to prevent and/or treat radiation optic neuropathy and maculopathy.

 
Conclusions:
 

At The New York Eye Cancer Center, palladium-103 ophthalmic plaque brachytherapy has provided local control and eye retention rates equivalent to or superior than published alternative radiation methods. Our visual acuity outcomes are markedly superior (Table).  

 
Keywords: melanoma • uvea • radiation therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×